TuHURA Biosciences Email Formats

About TuHURA Biosciences

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer. TuHURA’s Immune Fx™, or IFx™, personalized cancer vaccine technology is designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria thereby harnessing the power of the innate immune response by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses. TuHURA’s personalized cancer vaccines are delivered either via intratumoral injection using The Company’s pDNA vaccine or tumor targeted via intravenous using The Company’s mRNA vaccine. TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-functional antibody drug conjugates (ADCs), targeting Myeloid Derived Suppressor Cells (MDSCs) to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The Company’s Delta receptor technology was developed at Moffitt Cancer Center, West Virginia University and TuHURA Biopharma.

View contact profiles from TuHURA Biosciences